顺铂联合培美曲塞一线治疗老年晚期肺腺癌的临床疗效及安全性分析

Clinical efficacy and safety analysis of cisplatin plus pemetrexed for first-line treatment of elderly patients with advanced lung cancer

目的探讨顺铂联合培美曲塞一线治疗老年晚期肺腺癌的临床疗效与安全性。方法选取2012年8月至2013年8月间收治的80例老年晚期肺腺癌患者,采取随机数字表法分为对照组和观察组,每组40例。对照组患者给予顺铂联合吉西他滨治疗,观察组患者给予顺铂联合培美曲塞治疗,对比两组患者的近期疗效、不良反应及生存率。结果观察组患者的总有效率为70.0%,对照组为52.5%,差异有统计学意义(2=5.46,P<0.05)。观察组与对照组患者的胃肠道反应、白细胞降低及血小板降低的发生率差异有统计学意义(均P<0.05)。观察组与对照组患者静脉炎发生率差异无统计学意义(P>0.05)。观察组与对照组患者治疗3个月、6个月后的生存率差异无统计学意义(P>0.05)。观察组与对照组患者治疗12个月后的生存率差异有统计学意义(P<0.05)。结论顺铂联合培美曲塞治疗老年晚期肺腺癌的临床疗效显著,不良反应较少,安全性高,随访生存率较高,值得推广。

Objective To explore the clinical efficacy and safety analysis of cisplatin and pemetrexed for first-line treatment of elderly patients with advanced lung cancer. Methods A total of 80 elderly patients with advanced lung cancer patients treated in People＇s Hospital of Linqu County from August 2012 to August 2013 were enrolled,were randomly divided into control group and observation group,40 cases in each group. The control group was given cisplatin gemcitabine treatment,observation group received cisplatin pemetrexed therapy. Short-term efficacy,adverse reactions and follow-up of survival of the two groups were compared. Results The total effective rate was 70. 0% in the control group,52. 5% in observation group. There was significant difference between the two groups（ P〈0. 05）. There was significant difference between the two groups in gastrointestinal reactions,leukopenia and thrombocytopenia（ P〈0. 05）. There was no significant difference between the two groups in the incidence of phlebitis（ P〉0. 05）. There was no significant difference between the two groups in three months and six months survival rates（ P〉0. 05）.There was significant difference between the two groups in 12 months survival rates（ χ^2= 4. 73,P〈0. 05）.Conclusions The clinical efficacy of cisplatin plus pemetrexed treatment of elderly patients with advanced lung adenocarcinoma was significantly fewer adverse reactions,higher safety,follow-up survival,and is worthy of clinical promotion.